Briefing
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
Recruiting phase 2 trial (ReACT) of risk-adapted therapy in HPV-positive oropharyngeal cancer using a circulating tumor HPV DNA profile. No primary efficacy paper was identified.
- Design: Phase 2 · Recruiting